CoChat

The DOI matches its Crossref record; 355 of the 355 references it cites were found in a registry or an index.

Wnt/β-catenin signaling pathway in carcinogenesis and cancer therapy

Open access
Song, Pan, Gao, Zirui, Bao, Yige, Chen, Li, Huang, Yuhe, Liu, Yanyan, Dong, Qiang, Wei, Xiawei · 2024 · Journal of Hematology & Oncology

Abstract

The Wnt/β-catenin signaling pathway plays a crucial role in various physiological processes, encompassing development, tissue homeostasis, and cell proliferation. Under normal physiological conditions, the Wnt/β-catenin signaling pathway is meticulously regulated. However, aberrant activation of this pathway and downstream target genes can occur due to mutations in key components of the Wnt/β-catenin pathway, epigenetic modifications, and crosstalk with other signaling pathways. Consequently, these dysregulations contribute significantly to tumor initiation and progression. Therapies targeting the Wnt/β-catenin signaling transduction have exhibited promising prospects and potential for tumor treatment. An increasing number of medications targeting this pathway are continuously being developed and validated. This comprehensive review aims to summarize the latest advances in our understanding of the role played by the Wnt/β-catenin signaling pathway in carcinogenesis and targeted therapy, providing valuable insights into acknowledging current opportunities and challenges associated with targeting this signaling pathway in cancer research and treatment.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s13045-024-01563-4

Cites

355 of 355 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Wnt/β-catenin signaling pathway mechanism. Under normal physiological conditions, cytoplasmic β-catenin is phosphorylated by a destruction complex composed of APC, AXIN, GSK3β, CK1α, and the E3 ubiquitin ligase β-TrCP. In this degradation complex, GSK3β and CK1α mediate the phosphorylation of β-catenin, leading to its ubiquitination and subsequent proteasomal degradation. In the presence of Wnt binding, the FZD receptor is activated, which subsequently recruits DVL to the plasma membrane. DVL then interacts with AXIN, leading to the recruitment and accumulation of a complex at the receptor site. This receptor complex inhibits the activity of the β-catenin destruction complex (DC). As a result, β-catenin accumulates in the cytoplasma and is then transported to the nucleus, where it accumulates and interacts with TCF/LEF and coactivators to activate Wnt target genes
Fig. 1 Wnt/β-catenin signaling pathway mechanism. Under normal physiological conditions, cytoplasmic β-catenin is phosphorylated by a destruction complex composed of APC, AXIN, GSK3β, CK1α, and the E3 ubiquitin ligase β-TrCP. In this degradation complex, GSK3β and CK1α mediate the phosphorylation of β-catenin, leading to its ubiquitination and subsequent proteasomal degradation. In the presence of Wnt binding, the FZD receptor is activated, which subsequently recruits DVL to the plasma membrane. DVL then interacts with AXIN, leading to the recruitment and accumulation of a complex at the receptor site. This receptor complex inhibits the activity of the β-catenin destruction complex (DC). As a result, β-catenin accumulates in the cytoplasma and is then transported to the nucleus, where it accumulates and interacts with TCF/LEF and coactivators to activate Wnt target genesCC BY · PubMed Central
Fig. 2 Aberrant Wnt/β-catenin signaling pathway activation in tumor. Genetic abnormalities and epigenetic modifications can activate the Wnt/β-catenin pathway, leading to the onset of tumorigenesis. Mutations of tumor suppressor genes decrease the activity of the destruction complex, contributing to tumor growth. RNF43 loss-of-function mutations that increase Wnt receptor abundance on the cell surface, rendering tumors sensitive to Wnt inhibitors and decreasing negative feedback at the receptor-level to drive tumor growth. Loss of DNA methylation results in aberrant transcription of target genes, including WIF1, SFRP, DKK1, DACT, SOX7/17, β-TrCP, E-Cadherin, APC, AXIN-2, Wnt7a/9A. Histone modifications, such as methylation, acetylation, and phosphorylation, regulate the Wnt/β-catenin signaling pathway in tumors by controlling chromatin accessibility and gene expression of Wnt pathway components and downstream targets, impacting tumor initiation, progression, and metastasis. Non-coding RNA, including lncRNA and miRNA, modulate the Wnt/β-catenin signaling pathway in tumors by targeting key components such as β-catenin, Wnt ligands, receptors, and genes
Fig. 2 Aberrant Wnt/β-catenin signaling pathway activation in tumor. Genetic abnormalities and epigenetic modifications can activate the Wnt/β-catenin pathway, leading to the onset of tumorigenesis. Mutations of tumor suppressor genes decrease the activity of the destruction complex, contributing to tumor growth. RNF43 loss-of-function mutations that increase Wnt receptor abundance on the cell surface, rendering tumors sensitive to Wnt inhibitors and decreasing negative feedback at the receptor-level to drive tumor growth. Loss of DNA methylation results in aberrant transcription of target genes, including WIF1, SFRP, DKK1, DACT, SOX7/17, β-TrCP, E-Cadherin, APC, AXIN-2, Wnt7a/9A. Histone modifications, such as methylation, acetylation, and phosphorylation, regulate the Wnt/β-catenin signaling pathway in tumors by controlling chromatin accessibility and gene expression of Wnt pathway components and downstream targets, impacting tumor initiation, progression, and metastasis. Non-coding RNA, including lncRNA and miRNA, modulate the Wnt/β-catenin signaling pathway in tumors by targeting key components such as β-catenin, Wnt ligands, receptors, and genesCC BY · PubMed Central
Fig. 3 Timeline of clinical trials for agents targeting the Wnt/β-catenin signaling pathway
Fig. 3 Timeline of clinical trials for agents targeting the Wnt/β-catenin signaling pathwayCC BY · PubMed Central
Fig. 4 Therapeutic strategies targeting Wnt/β-catenin signaling pathway. Currently, many Wnt/β-catenin signaling pathway inhibitors have become potential anti-cancer therapeutic drugs and are currently undergoing preclinical or clinical research. These drugs work by targeting specific components of the canonical Wnt signaling pathway, causing downregulation of Wnt signaling and inhibiting cancer progression. The selection of Wnt activators or inhibitors is crucial. In terms of specific target components within the pathway, these drugs can be divided into the following categories: (1) Extracellular or membrane level inhibitors or antagonists, which target Wnt. Ligands: FZD, LRP5/6 (2). Cytoplasmic level inhibitors, targeting β-catenin, AXIN, APC and other components involved in pathway activation; (3) Nuclear level inhibitors, regulating the transcription of target genes, such as transcriptional co-factors; (4) Inhibitors that interact with other signaling pathways
Fig. 4 Therapeutic strategies targeting Wnt/β-catenin signaling pathway. Currently, many Wnt/β-catenin signaling pathway inhibitors have become potential anti-cancer therapeutic drugs and are currently undergoing preclinical or clinical research. These drugs work by targeting specific components of the canonical Wnt signaling pathway, causing downregulation of Wnt signaling and inhibiting cancer progression. The selection of Wnt activators or inhibitors is crucial. In terms of specific target components within the pathway, these drugs can be divided into the following categories: (1) Extracellular or membrane level inhibitors or antagonists, which target Wnt. Ligands: FZD, LRP5/6 (2). Cytoplasmic level inhibitors, targeting β-catenin, AXIN, APC and other components involved in pathway activation; (3) Nuclear level inhibitors, regulating the transcription of target genes, such as transcriptional co-factors; (4) Inhibitors that interact with other signaling pathwaysCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Show all 355 references

Research works printed but not linked: 6

  1. Nusse R, Clevers H. Wnt/beta-Catenin signaling, disease, and emerging therapeutic modalities. Cell. 2017;169(6):985–99. · DOI · Paper page
  2. Cai J, Fang L, Huang Y, Li R, Xu X, Hu Z, et al. Simultaneous overactivation of Wnt/β-catenin and TGFβ signalling by mir-128-3p confers chemoresistance-associated metastasis in NSCLC. Nat Commun. 2017;8:15870. · DOI · Paper page
  3. Chai S, Ng KY, Tong M, Lau EY, Lee TK, Chan KW, et al. Octamer 4/microRNA-1246 signaling axis drives Wnt/β-catenin activation in liver cancer stem cells. Hepatology. 2016;64(6):2062–76. · DOI · Paper page
  4. Wang Z, Li Z, Ji H. Direct targeting of β-catenin in the wnt signaling pathway: current progress and perspectives. Med Res Rev. 2021;41(4):2109–29. · DOI
  5. Jung YS, Park JI. Wnt signaling in cancer: therapeutic targeting of wnt signaling beyond β-catenin and the destruction complex. Exp Mol Med. 2020;52(2):183–91. · DOI · Paper page
  6. Zhao H, Ming T, Tang S, Ren S, Yang H, Liu M, et al. Wnt signaling in colorectal cancer: pathogenic role and therapeutic target. Mol Cancer. 2022;21(1):144. · DOI · Paper page

Cited by

See all 454

Metadata

Authors
Song, P., Gao, Z., Bao, Y., Chen, L., Huang, Y., Liu, Y., Dong, Q., & Wei, X.
Affiliations
  • West China Hospital of Sichuan University (CN)
  • Sichuan University (CN)
Corresponding author
  • Dong, Qiang
  • Wei, Xiawei
Venue
Journal of Hematology & Oncology
Published
2024-06-18
Volume
17
Issue
1
Pages
46-46
ISSN
1756-8722 (ISSN-L)
OpenAlex
W4399792819
Cited by
382
References
354
Citations by year
2026: 167 · 2025: 193 · 2024: 22
FWCI
15.54
Type
journal article
Language
en
Open access
Licence
Locations
  • Journal of Hematology & Oncology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Funders
  • National Science Foundation for Excellent Young Scholars (32122052)
  • National Natural Science Foundation Regional Innovation and Development (No. U19A2003)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Wnt/β-catenin signaling in development and cancer
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Signaling Pathways in Disease
Keywords
Wnt/β-catenin signaling, carcinogenesis, cancer therapy, targeted therapy, tumor initiation and progression, epigenetic modifications, signaling crosstalk, Wnt inhibitors, cell proliferation, tissue homeostasis
MeSH terms
Animals, Antineoplastic Agents, Humans, Neoplasms, beta Catenin, Molecular Targeted Therapy, Wnt Signaling Pathway, Carcinogenesis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Wnt/β-catenin signaling pathway in carcinogenesis and cancer therapy. https://app.cochat.ai/papers/10.1186/s13045-024-01563-4
The paper
Song, P., Gao, Z., Bao, Y., Chen, L., Huang, Y., Liu, Y., Dong, Q., & Wei, X. (2024). Wnt/β-catenin signaling pathway in carcinogenesis and cancer therapy. Journal of Hematology & Oncology. https://doi.org/10.1186/s13045-024-01563-4

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.